Clinical Trial Update: A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial of relatlimab plus nivolumab in high-risk clinical stage II cutaneous melanoma; the study is currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma

Drugs mentioned

• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: Melanoma Institute Australia | Conditions: Stage II Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING